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Method validationAbstract The aim of the paper was to formulate a combined oral dosage form of rosuvastatin cal-
cium and amlodipine besylate and to develop and validate an analytical method to be adopted for
both routine quality control assay and in vitro dissolution studies of the formulation.
The proposed combination formulation has shown compatibility with the chosen excipients, ver-
iﬁed through FT-IR study. A novel gradient RP-HPLC method was developed and validated
according to the ICH guideline which was found to be suitable for the simultaneous estimation
of rosuvastatin calcium and amlodipine besylate from the formulation. The retention time of 2.7
and 6.08 min allows the analysis of large amount of samples with less mobile phase which makes
the method economic. The dissolution proﬁles of both the drugs in different dissolution medium
were encouraging which makes the combination formulation of rosuvastatin calcium and amlodip-
ine besylate superior and effective in achieving patient compliance.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).HMG-
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Figure 1 Structure of rosuvastatin calcium.
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Cardiovascular diseases such as coronary heart disease, cere-
brovascular disease, atherothrombosis, ischemic heart disease,
and peripheral arterial disease are found to be prevalent
among different age groups of people especially among the
young generation. According to a report by Saquib et al.,
the death rate from cardiovascular diseases (CVD) would be
4 times higher in 2010 and 21 times higher in 2025 compared
to its corresponding rate in 2003 (Saquib et al., 2012). Hyper-
tension and dyslipidemia are important, modiﬁable cardiovas-
cular (CV) risk factors that frequently coexist, and together
have an effect on CV risk that may be greater than expected
from the simple addition of the risk associated with each con-
dition (Blank et al., 2005).
2. Need of combination therapy
Novel drug delivery systems are constantly being developed for
various purposes such as the expansion of markets and indica-
tions, the extension of product life cycles, or the generation of
opportunities. Even after advancement in the management of
cardiovascular diseases (CVD) during the last several years,
they are still the main cause for morbidity and mortality
(Gowda et al., 2012). Many hypertensive symptoms of hyper-
lipidemic patients may be reduced using the combination for-
mulation of antihyperlipidemic and antihypertensive agents.
Combined dosage form of two or more drugs has been proven
useful in multiple therapies as they offer better patient compli-
ance than a single drug. It is well recognized that a single drug,
even when used in maximal recommended dosage will control
no more than 50% of a hypertensive population (Shaikh et al.,
2010). On the other hand, the skillful use of two or more
agents in combination can improve hypertension control rates
to well above 80% (Shaikh et al., 2010). Therefore, the rational
for combination therapy is to encourage the use of lower doses
of drug to reduce patient’s blood pressure with the goal to min-
imize dose dependent side effects and adverse reactions (Atram
et al., 2009). The ﬁxed-dose combination containing the anti-
hypertensive agent amlodipine and the cholesterol lowering
agent atorvastatin is the ﬁrst combination of its kind designed
to treat two risk factors for cardiovascular disease (Bashir
et al., 2011). Atorvastatin has rapid access to non-hepatic tis-
sues due to the hydrophobicity which results in some undesir-
able side effects. These unwanted side effects associated with
combined dosage of atorvastatin and amlodipine may be
reduced when rosuvastatin is used in place of atorvastatin.
An assortment of techniques has been described for the quan-
tiﬁcation of rosuvastatin alone or in combination with other
products (Gowda et al., 2012). The reverse phase-high perfor-
mance liquid chromatography (RP-HPLC) methods described
for simultaneous determination of rosuvastatin and amlodip-
ine in pharmaceutical preparations (Banerjee and Vasava,
2013; Tajane et al., 2012) however, is not developed for
in vitro dissolution proﬁle of rosuvastatin calcium and
amlodipine besylate from their combination drug products.
Since no systemic studies on the design and development of
such a combination formulation or its in vitro dissolution
study are currently available in literature, we took an attempt
to develop a suitable formulation and assay method which can
be used further to characterize the in vitro dissolution proﬁle ofrosuvastatin calcium and amlodipine besylate. Therefore, a
simple, accurate, efﬁcient and reproducible reverse phase
HPLC method has been developed and validated for the simul-
taneous determination of rosuvastatin calcium and amlodipine
besylate at 240 nm in combined tablet dosage form and has
been applied successfully for in vitro dissolution studies.
Rosuvastatin, chemically described as bis [(E)-7 [4-(4-
ﬂuorophenyl)-6 isopropyl-2[methyl (methyl-sulphonyl) amino]
pyrimidin-5-yl] (3R, 5S) -3, 5-dihydroxyhept-6-enoic acid]
(Fig. 1), is another member of the drug class statin. It is hydro-
philic and this makes it hepatoselective. This drug may thus be
considered as a substitute of atorvastatin to formulate a new
combination of drug for dose-related reduction in systolic
blood pressure, diastolic blood pressure and low density
lipoprotein cholesterol in patients with co-morbid hyperten-
sion and dyslipidemia. It competitively inhibits HMG-CoA
reductase enzyme that catalyzes the conversion of HMG-
CoA to mevalonate, an early rate-limiting step in cholesterol
biosynthesis (Reddy et al., 2011).
Amlodipine besylate, chemically described as 3-ethyl-5-me
thyl(±)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dih
ydro-6-methyl-3,5 pyridinedicarboxylate, monobenzene-
sulphonate (Fig. 2), is a long-acting dihydropyridine class of
calcium channel blocker, approved for treating hypertension
and both vasospastic and chronic, stable angina (Blank
et al., 2005). It selectively inhibits the transmembrane inﬂux
of Ca2+ ion across L-type calcium channels, without changing
serum calcium concentration. Thus it relaxes the muscles lining
the arteries and lowers blood pressure. It also expands coro-
nary arterioles which increases the ﬂow of blood to the heart
and prevents heart pain (angina) resulting from reduced ﬂow
of blood to the heart that is caused by coronary artery spasm
(contraction). It is more vasoselective with lower negative ino-
tropic effects and reﬂex tachycardia is less prominent since
ﬂuctuations in plasma levels are less pronounced with these
agents (Drug information reference, 2003).
3. Materials and methods
The present research started with the development of a pro-
posed combination formulation of a statin with a calcium
channel blocker. Excipients, used for the preparation of the
combined formulation tablets of rosuvastatin and amlodipine,
were initially chosen on the basis of the existing formulation of
atorvastatin and amlodipine and their compatibility with the
Figure 2 Structure of amlodipine besylate.
The analysis of a combination formulation 691active ingredients veriﬁed using FTIR study. When the results
came positive, the proposed formulation of the statin with the
calcium channel blocker was adopted as the combination for-
mulation and this was further studied. An assay based method
was then developed and validated for the simultaneous estima-
tion of rosuvastatin and amlodipine from the combination for-
mulation which has been used further to characterize the
in vitro dissolution proﬁle of rosuvastatin calcium and
amlodipine besylate.
3.1. Chemical and pharmaceutical preparation
Reference standard of rosuvastatin calcium and amlodipine
besylate was donated by the two of the leading local pharmaceu-
tical companies of Bangladesh, Square Pharmaceuticals Lim-
ited, Bangladesh and Eskayef Bangladesh Limited, which are
certiﬁed to be 96.36% and 99.33% pure respectively. The test
tablets of the combination formulation of 10 mg rosuvastatin
calcium and 5 mg amlodipine besylate used were manufactured
in-house. The excipients needed to make the tablets were gifted
from Eskayef Bangladesh Limited and ACI Limited. The com-
mercially available preparation of rosuvastatin (label claim
rosuvastatin calcium INN equivalent to rosuvastatin 10 mg)
and amlodipine (label claim 5 mg amlodipine) used in the anal-
ysis, were collected from the localmarket. Thewater used for the
preparation of buffer was puriﬁed by distillation. All the sol-
vents used for the study were of HPLC grade.Figure 3 FT-IR study of rosu3.2. Instrumentation
The HPLC system consisted of a high pressure binary gradient
pump (LC-20AT; Shimadzu), SIL-20AHT auto sampler,
CTO-10ASvp column temperature oven, SPD-M20A PDA
detector has been used for doing all the experiments including
the development and its subsequent validation. All the compo-
nents of the system are controlled by using CBM-20 Alite sys-
tem controller. Data acquisition was done using lab solution
LC workstation multi PDA software. The dissolution test
was carried out using Universal Dissolution Tester (model:
UDT 804-B).
3.3. Compatibility studies
The drug-excipient compatibility studies were done to select
the excipients that are physically and chemically compatible
with the API, using Fourier Transform Infrared spectroscopy.
This was done by separately mixing each drug entity with the
individual excipient in the ratio of 1:1. A separate FT-IR study
of the standard sample of rosuvastatin calcium and amlodipine
besylate was also done. The IR spectrum exhibiting the trans-
mittance of different functional groups of the pure sample of
rosuvastatin and amlodipine within 4000–400 cm1 region
was checked, studied and recorded (Figs. 3 and 4) and their
comparison with the IR spectrum exhibiting transmittance of
those same functional groups was done in presence of each
of the excipients individually (Tables 1 and 2).
3.4. HPLC method
A reversed phase HPLC system was used to analyze both com-
pounds with a sufﬁcient separation and a ﬁne peak shape
owing to the relatively nonpolar properties of rosuvastatin cal-
cium and amlodipine besylate. Therefore, all the experiments
were carried out on a Luna 5l C18 column
(250 mm · 4.60 mm) at ambient temperature using different
conditions of various mobile phases systematically. The mobile
phase systems that were initially ﬁxed after extensive literaturevastatin calcium standard.
Figure 4 FT-IR study of amlodipine besylate standard.
Table 1 FT-IR study of rosuvastatin calcium (standard) and its comparison with the mixed sample of rosuvastatin calcium and
individual excipient.
OAH stretching Dual response S‚O stretching
ALCOHOL 3300–2500 SULFONE
Broad & strong OAH stretching Strong
3550–3200 Carboxylic acid 1160–1120
3200–2700
OAH stretching
Alcohol
(intramolecular bonded)
Rosuvastatin calcium (standard) 3420.87 2969.55 2928.04 1156.36
RSV+ pregelatinized modiﬁed starch 3420.87 2968.55 2931.90 1155.40
RSV+microcrystalline cellulose 3420.87 2966.62 2930.93 1156.36
RSV+ sodium starch glycolate 3440.16 2968.55 2930.93 1155.40
RSV+ colloidal SiO2 3433.41 2969.51 2934.79 1113.93
RSV+ butylated hydroxyanisole 3421.83 2952.15 2915.5 1156.36
RSV+magnesium stearate 3428.76 2956.97 2916.47 1156.36
692 N. Mubtasim et al.review, focusing on the gradient elution of rosuvastatin and
amlodipine, are as follows:
(i) Phosphate buffer (pH 2.5): acetonitrile in the ratio
55:45% v/v (Banerjee and Vasava, 2013).
(ii) Acetonitrile: THF: water at pH 3 in the ratio 68:12:20%
v/v (Tajane et al., 2012).
The suitable wavelength for detection of rosuvastatin cal-
cium and amlodipine besylate was selected from the overlain
spectrum of rosuvastatin and amlodipine.
3.5. Preparation of solutions for assay
3.5.1. Standard preparation
Standard stock solution of rosuvastatin and amlodipine was
prepared by dissolving 25 mg rosuvastatin and 12.5 mgamlodipine respectively with a small quantity of mobile phase
into a clean dry 100 ml volumetric ﬂask. It was then sonicated
for 20 min and the ﬁnal volume of the solution was then made
up to 100 ml with the mobile phase. 4 ml solution was taken
into 100 ml volumetric ﬂask to obtain a concentration of
10 lg/ml rosuvastatin and 5 lg/ml amlodipine.
3.5.2. Sample preparation
A total of 20 tablets were accurately weighed and powdered in a
clean dry mortar. An amount equivalent to 10 mg of rosuvas-
tatin and 5 mg of amlodipine was taken in a conical ﬂask and
dissolved in small quantity of mobile phase with the aid of ultra-
sonication for 15 min. The resultant solution was then ﬁltered,
throughWhatman ﬁlter paper, into a clean, dry 100 ml volumet-
ric ﬂask and the ﬁnal volume was made up to 100 ml with the
mobile phase. From the solution, 1 ml was taken out into
10 ml volumetric ﬂask and dilution was done with the mobile
Table 2 FT-IR study of amlodipine besylate (standard) and its comparison with the mixed sample of amlodipine besylate and
individual excipients.
NAH stretching NAH stretching CAH stretching C‚O stretching S‚O stretching
Medium Medium Strong Strong Strong
Primary amine Secondary amine Alkene a, b-unsaturated ester Sulfone
3330–3250 3350–3310 3100–3000 1730–1715 1160–1120
Amlodipine besylate (standard) 3300.31 3157.58 3069.81 1696.45 1125.5
AMD besylate + pregelatinized modiﬁed starch 3285.85 3155.65 3066.92 1696.45 1125.5
AMD besylate + microcrystalline cellulose 3420.91 3169.15 3066.92 1696.45 1125.5
AMD besylate + sodium starch glycolate 3291.63 3155.65 3083.31 1696.45 1125.50
AMD besylate + colloidal SiO2 3290.76 3155.67 3085.61 1696.45 1125.5
AMD besylate + butylated hydroxyanisole 3329.25 3154.68 3068.85 1696.45 1125.5
AMD besylate +Mg stearate 3292.60 3164.33 3066.92 1696.45 1125.50
Figure 5 Chromatogram of rosuvastatin calcium and amlodipine besylate reference standard.
Table 3 System suitability study of rosuvastatin calcium.
Rosuvastatin calcium
Tailing
factor
Theoretical
plate
Peak
area
Retention
time
Average 1.153 6359 140,766 6.187
STD 0.017 36.73 33.13 0.006
RSD
(%)
1.45 0.578 0.024 0.089
Table 4 System suitability study of amlodipine besylate.
Amlodipine besylate
Tailing
factor
Theoretical
plate
Peak
area
Retention
time
Average 1.035 10,737 160,458 2.594
STD 0.003 18.97 313.42 0.002
RSD
(%)
0.28 0.177 0.195 0.082
The analysis of a combination formulation 693phase to get a concentration of 10 lg/ml rosuvastatin and
5 lg/ml amlodipine. From this solution further dilutions were
done and injected into the system to get the chromatogram.3.6. Method validation
The suggested RP-HPLC method was validated with respect to
the corresponding parameters such as linearity, accuracy, pre-
cision, sensitivity, ruggedness, and robustness according to
USP and ICH guidelines.
3.7. In-vitro dissolution study
The in vitro dissolution study of the combined formulation of
rosuvastatin calcium and amlodipine besylate, was carried out
using USP-type II dissolution test apparatus. The drug release
study was conducted using two different dissolution media to
ascertain their percentage of release according to the respective
dissolution proﬁle mentioned in FDA reports. For the study of
dissolution proﬁle of rosuvastatin, 900 ml 0.05 M sodium citrate
buffer of pH 6.6 was used as the dissolution medium where agi-
tation speed of 50 rpm was maintained at (37 ± 0.5) C for
60 min; and for amlodipine 500 ml 0.01 N HCl was used as dis-
solution medium with agitation speed of 75 rpm, maintained
also at temperature (37 ± 0.5) C for 60 min. Aliquots of about
10 ml had been withdrawn after 10, 20, 30, 45 and 60 min and
ﬁltered. The ﬁltrates were then ﬁnally ﬁltered through 0.2 l disk
ﬁlter and prepared vials were analyzed with the validated
RP-HPLC method for assay. The dissolution proﬁle of the
y = 16237620x - 3055.68
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Figure 6 Calibration curve of rosuvastatin calcium.
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Figure 7 Calibration curve of amlodipine besylate.
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ine was compared with that of separate commercial prepara-
tions of amlodipine and rosuvastatin alone.
4. Result & discussion
4.1. IR spectral analysis
The compatibility study of rosuvastatin calcium and amlodip-
ine besylate with the selected excipients came out positive
which enabled us to adopt the formula to formulate the com-
bination dosage form.
4.2. Chromatographic conditions
The mobile phase composition of phosphate buffer (pH 2.5)
and acetonitrile in the ratio 55:45% v/v that was set at a ﬂow
rate of 1.5 ml/min was chosen because it was found optimal toTable 5 Linearity, accuracy, precision, ruggedness, LOD, and LOQ
Validation parameters
Linearity Linear equation
Correlation coeﬃcient (R2)
Accuracy % of recovery 80%
100%
120%
Precision Interday precision peak area (%RSD)
Intraday precision peak area (%RSD)
Ruggedness Peak area (%RSD) Analyst 1
Analyst 2
LOD Concentration (lg/ml)
LOQ Concentration (lg/ml)resolve the peak at 240 nm with retention time 2.7 min and
6.08 min for amlodipine and rosuvastatin respectively
(Fig. 5). 10 ll samples were injected at each run.
4.3. Method validation
4.3.1. System suitability test
Freshly prepared samples of rosuvastatin calcium and
amlodipine besylate were injected six times into the chromato-
graphic system under the optimized chromatographic condi-
tions to check all the important parameters such as column
efﬁciency (theoretical plates), peak tailing, retention factor,
and resolution. The % RSD for the peak area (Tables 3 and
4) response was found to be less than 2%.
4.3.2. Linearity
The linearity of calibration curves was established by plotting
a graph between concentrations versus corresponding peak
area of the sample (Figs. 6 and 7) and co-relation coefﬁcient,
slope and y-intercept were determined. Five different concen-
trations of sample solutions were prepared in the concentra-
tion range of 80%, 90%, 100%, 110%, and 120% from the
standard stock solution of rosuvastatin calcium and amlodip-
ine besylate and injected into the HPLC system. The detector
response was found to be linear with 8 lg/ml to 1.2 lg/ml con-
centration of rosuvastatin calcium and the 4 lg/ml to 6 lg/ml
concentration of amlodipine besylate. The co-relation coefﬁ-
cient was found to be 0.992 for rosuvastatin and 0.995 for
amlodipine (Table 5).
4.3.3. Accuracy
The accuracy of the assay method was evaluated with the
recovery of the standards from excipients (Tajane et al.,
2012). Accuracy was carried out at three concentrations i.e.
80%, 100% and 120% of the target concentration of both
the drugs. The concentration of solutions were prepared and
injected six times. The mean percentage of recovery (Table 5)
for both the drugs was found to range from 98% to 102%
for both rosuvastatin and amlodipine which suggests the accu-
racy of the method for their simultaneous estimation.
4.3.4. Precision
The intraday and interday precisions were assessed by multiple
sampling of homogenous sample of 10 lg/ml rosuvastatin
calcium and of 5 lg/ml amlodipine besylate. The percentagestudy of rosuvastatin calcium and amlodipine besylate.
(Rosuvastatin calcium) Amlodipine besylate
y= 16237620x  3055.68 y= 12563120x+ 1103.8
0.992949109 0.995915782
102.88% 102.88%
101.97% 101.97%
98.67% 98.67%
0.099 0.222
0.099 0.149
1.187 1.187
1.20 1.20
0.06 0.018
0.22 0.095
Table 6 Robustness study of rosuvastatin calcium and
amlodipine besylate.
Conditions Retention
time
Peak area Tailing
factor
Average %RSD
Rosuvastatin calcium
ACN:Buﬀer (48:52) 8.285 158,392 0.224 1.060
ACN:Buﬀer (42:58) 5.166 155,370 0.076 1.023
Flow rate (1.3 ml/min) 6.356 72,352 0.04 1.045
Flow rate (1.7 ml/min) 5.654 139,265 0.10 1.040
Column temperature
(20 C)
6.495 157,389 0.075 1.042
Column temperature
(30 C)
6.234 157,247 0.096 1.052
Wavelength (235 nm) 6.315 157,443 0.151 1.045
Wavelength (245 nm) 6.345 157,622 0.178 1.047
Amlodipine besylate
ACN:Buﬀer (48:52) 2.405 62,771 0.213 1.133
ACN:Buﬀer (42:58) 3.411 62,786 0.098 1.203
Flow rate (1.3 ml/min) 3.130 72,348 0.036 1.187
Flow rate (1.7 ml/min) 2.431 55,437 0.084 1.169
Column temperature
(20 C)
2.673 63,159 0.737 1.185
Column temperature
(30 C)
2.799 63,432 0.124 1.189
Wavelength (235 nm) 2.765 63,175 0.161 1.184
Wavelength (245 nm) 2.759 63290.4 0.246 1.181
Table 7 Dissolution proﬁle of rosuvastatin calcium.
Time interval Dissolution media % of drug release
Formulated
combination
preparation
Market
preparation
Rosuvastatin calcium
After 10 min 0.05 M sodium
citrate buﬀer of
pH 6.6
88.03 83.89
After 20 min 91.65 90.86
After 30 min 94.06 92.7
After 45 min 96.99 94.07
After 60 min 98.5 98
The analysis of a combination formulation 695relative standard deviation (Table 5) was found to be less than
2% for both interday and intra-day precision (Sagar et al.,
2012).80
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Figure 8 Comparative drug release pattern of r4.3.5. Ruggedness
Ruggedness was determined by verifying the percentage rela-
tive standard deviation of the measurement of the two analysts
in the same laboratory. For this purpose, six replicate samples
were analyzed. The percentage relative standard deviation
(%RSD) was found to be less than 2% for both the drugs
(Table 5).
4.3.6. Sensitivity
Limit of detection (LOD) and limit of quantitation (LOQ)
were estimated from the signal-to-noise ratio (Hosseini,
2011). Limit of detection is deﬁned as the lowest concentration
of analyte resulting in a peak area three times that of the base-
line noise (Hosseini, 2011). On the other hand, the limit of
quantitation is deﬁned as lowest concentration of analyte that
provide a peak area that of ten times the baseline noise
(Hosseini, 2011). The LOD value for rosuvastatin calcium
and amlodipine besylate was found to be 0.06 lg/ml and
0.018 lg/ml and the LOQ value for rosuvastatin calcium and
amlodipine besylate was found to be 0.095 lg/ml and
0.22 lg/ml respectively (Table 5).
4.3.7. Robustness
The robustness of an analytical procedure was assessed by mea-
suring its capacity to remain unaffected by small but deliberate
variations in method parameters which provides an indication
of its reliability for routine analysis (Sagar et al., 2012). To deter-
mine robustness of the proposed method, test samples were pre-
pared and analyzed by varying analytical parameters while
keeping the other parameters unchanged such as the composi-
tion of mobile phase (±5%), ﬂow rate (±2%), column temper-
ature (±5 C), and wavelength (±5). None of the alteration
caused a signiﬁcant change in peak area, percentage of relative
standard deviation, tailing factor and retention time (Sagar
et al., 2012). The results are recorded in Table 6.
4.3.8. In vitro dissolution study
A typical acceptance criterion for dissolution release of drugs
from immediate release tablet is about 80% of label amount
in 45 min (Ummapathi et al., 2011). Both preparations (market
and the combination formulation) were found to release an
average of 95% rosuvastatin and 93% of amlodipine within
45 min (Tables 7 and 8), without showing any hindrance to
the release pattern of other drug (Fig. 8). The dissolution pat-
tern complies with the BP Guidance standards as well as with
the in-house speciﬁcations (rosuvastatin calcium is an INN0 
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Figure 9 Flowchart of the study design.
Table 8 Dissolution proﬁle of amlodipine besylate.
Time interval Dissolution
media
% of drug release
Formulated
combination
preparation
Market
preparation
Amlodipine besylate
After 10 min 0.01 N HCl 58.69 90.08
After 20 min 71.56 92.16
After 30 min 83.62 98
After 45 min 92.56 102
After 60 min 99.65 105
696 N. Mubtasim et al.drug), indicating suitability of the proposed method for the
dissolution study of the two drugs (see Fig. 9).
5. Conclusion
The proposed combination formulation of rosuvastatin cal-
cium and amlodipine besylate has shown compatibility with
the chosen excipients, veriﬁed through FT-IR study. A novel
gradient RP-HPLC method was developed and validated
according to the ICH guideline which was found to be suitable
for the simultaneous estimation rosuvastatin calcium and
amlodipine besylate from the combination formulation. The
retention time of 2.7 and 6.08 min allows the analysis of large
amount of samples with less mobile phase which makes the
method economic. The dissolution proﬁles of both the drugs
in different dissolution medium were encouraging which
makes the combination formulation of rosuvastatin calcium
and amlodipine besylate superior and effective in achieving
patient compliance. The complete design of the study done
can be depicted in a ﬂowchart as shown in Fig. 9.Acknowledgements
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